tirzepatide body composition Tirzepatide‐induced changes: Implications from the SURPASS‐3 MRI substudy Tirzepatide, Weight Loss Miracle Or

When to delay dose escalation Not everyone should increase their dose every four weeks

How to Tell If a GLP-1 Provider Is Cutting Corners Red Flags: No lab requirement before prescribing Instant approval without medical history review One-size-fits-all dosing plans No follow-up or monitoring protocol Limited or no access to a licensed clinician Patients should feel empowered to ask: What data are you using to determine this is safe for me? Patient Scenarios: Real-World Context Case 1: Undiagnosed Prediabetes A patient begins semaglutide without labs

doi: 10.1371/journal.pone.0220506

The proportion of patients suffering from severe migraine disability fell from 61% to 30% in the active-treatment group (p=0.01) and from 54% to 47% in the placebo group (not significant)